[HTML][HTML] Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Importance Patients with cancer have an increased risk of severe disease and mortality from
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
Background Patients receiving hematopoietic stem cell transplantation (HSCT) or chimeric
antigen receptor T cell (CAR T-cell) therapy are immunocompromised and at high risk of …
antigen receptor T cell (CAR T-cell) therapy are immunocompromised and at high risk of …
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
X Wu, L Wang, L Shen, L He, K Tang - Journal of hematology & oncology, 2022 - Springer
Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
Hematopoietic cell transplantation (HCT) and cellular therapy (CT) recipients have poor
outcomes after developing COVID-19 (Spanjaart et al., 2021, Meir et al., 2021). HCT and/or …
outcomes after developing COVID-19 (Spanjaart et al., 2021, Meir et al., 2021). HCT and/or …
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an …
N Uaprasert, P Pitakkitnukun… - Blood Cancer …, 2022 - nature.com
Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
Adult patients with cancer have impaired humoral responses to complete and booster COVID-19 vaccination, especially those with hematologic cancer on active …
E Liatsou, I Ntanasis-Stathopoulos, S Lykos… - Cancers, 2023 - mdpi.com
Simple Summary Taking into consideration the high risk of patients with cancer for severe
COVID-19 infection, prioritization has been given to primary prevention with both primary …
COVID-19 infection, prioritization has been given to primary prevention with both primary …
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
More than 3 years have passed since Coronavirus disease 2019 (COVID‐19) was declared
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
J Bordat, S Maury, M Leclerc - Frontiers in immunology, 2023 - frontiersin.org
Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients are especially
vulnerable to coronavirus disease 19 (COVID-19), because of their profound …
vulnerable to coronavirus disease 19 (COVID-19), because of their profound …
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
D Sidler, A Born, S Schietzel, MP Horn, D Aeberli… - RMD open, 2022 - rmdopen.bmj.com
Background The majority of patients with B-cell-depleting therapies show compromised
vaccination-induced immune responses. Herein, we report on the trajectories of anti-SARS …
vaccination-induced immune responses. Herein, we report on the trajectories of anti-SARS …
Third BNT162b2 mRNA SARS-CoV-2 vaccine dose significantly enhances immunogenicity in recipients of allogeneic hematopoietic stem cell transplantation
I Henig, J Isenberg, D Yehudai-Ofir, R Leiba… - Vaccines, 2023 - mdpi.com
COVID-19-related mortality among hematopoietic stem cell transplantation (HSCT)
recipients in the pre-vaccine era ranged between 22 and 33%. The Pfizer/BioNTech …
recipients in the pre-vaccine era ranged between 22 and 33%. The Pfizer/BioNTech …